Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New York ephedra bill

This article was originally published in The Tan Sheet

Executive Summary

Legislation to "ban the sale of supplements that contain ephedra in New York State except for the drugs under FDA supervision" recently introduced in state assembly. FDA's recent warning label proposal "fails to adequately address the risks" of ephedra, assemblywoman Audrey Pheffer says in March 19 comments to FDA urging national ban of the botanical. Bill A 6921, introduced March 12, would institute fines "of not more than $500 per violation" and statewide ban would apply to synthetic and natural forms sold as "Sea Grape, Yellow Horse, Country Mallow...Teamster's Tea and Yellow Astringent," among others, legislation states...

You may also be interested in...



NYC ephedra bill

Persons selling herbal ephedra products could be subject to criminal fines of up to $1,000 in addition to civil fines of up to $1,000 under legislation introduced in New York City Council April 30 by minority leader James Oddo (R-Staten Island) and others. Ban would exempt FDA-approved OTCs, certified alternative medical practitioners, although it would not allow practitioners to prescribe botanical for weight loss, energy/athletic performance. Bill was referred to Health Committee. Similar measure banning ephedra was introduced in state assembly March 12 and referred to Codes Committee April 1 (1"The Tan Sheet" April 14, 2003, In Brief)...

Even As Acting US FDA Commissioner, Woodcock Still Holds Multiple Positions

To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.

Medicare Part D Protected Classes Targeted in Last-Minute Payment Demo Update

If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel